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ABSTRACT  
Background: Freezing of gait (FOG) is a debilitating gait disorder in Parkinson‟s disease 
(PD) with partial responsiveness to dopaminergic medication. To date, notions about the 
effects of subthalamic deep brain stimulation (STN-DBS) on FOG remain controversial. 
Objectives: To compare the effects of bilateral STN-DBS and continued best medical 
treatment (BMT) on FOG occurrence, FOG severity and clinical outcomes in PD patients at 6 
and 12 months follow-up.  
Methods: In this prospective, controlled study, 41 PD patients with at least 5 years disease 
duration participated. Twenty-four subjects (20 with FOG) were treated with STN-DBS and 
17 (15 with FOG) continued BMT. The primary outcome was the New Freezing of Gait 
Questionnaire (NFOGQ) at 6 months post-surgery. Other outcomes were the NFOGQ at 12 
months and clinical outcomes (UPDRS III, timed gait, falls and quality of life) at both time 
points.  
Results: STN-DBS increased the likelihood to convert from being a freezer to a non-freezer 
at 6 and 12 months follow-up (RRR=0.4). However, 45% of baseline freezers still 
experienced FOG 6 and 12 months post-surgery albeit with reduced severity. Three baseline 
non-freezers (1/2 BMT-treated, 2/4 STN-DBS-treated) developed FOG during follow-up. 
STN-DBS-induced benefits on FOG were mostly mediated by baseline levodopa equivalent 
dose, altered medication-intake and reduced motor fluctuations.  
Conclusions: In contrast to continued BMT, STN-DBS reduced FOG occurrence and severity 
at 6 months post-surgery with largely sustained effects at 12 months follow-up. Longer 
follow-up periods are needed to test whether FOG improvements after STN-DBS persist with 
disease progression. 
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INTRODUCTION  
Freezing of gait (FOG) is a common, debilitating symptom occurring mostly in the mid to 
later stages of Parkinson‟s disease (PD) and other parkinsonian syndromes.[1] The 
responsiveness of FOG to dopaminergic therapy varies between PD patients.[1, 2] FOG 
manifests itself mostly during off-periods but can also occur in on-periods.[1] Occasionally, 
pure on-FOG occurs only when the levodopa dose is increased.[2] High frequency deep brain 
stimulation (DBS) of the subthalamic nucleus (STN) is the most commonly applied surgical 
treatment in PD patients with levodopa-induced motor complications and dyskinesias.[3] 
Although the biophysical basis is incompletely understood, STN-DBS is thought to normalize 
pathological patterns of basal ganglia activity affecting thalamocortical and brainstem 
circuitries.[4, 5] STN-DBS improves Parkinsonian motor symptoms and quality of life, 
allowing a reduction in dopaminergic medication and thus reducing levodopa-induced 
complications.[6, 7] 
To date, the potentially beneficial effects of STN stimulation on FOG are less clear for three 
main reasons. First, laboratory assessment of FOG on and off stimulation is problematic due 
to its unpredictable nature and may not reflect FOG in daily life.[1] Second, both 
improvement and worsening of FOG have been reported depending on voltage/frequency 
stimulation settings and follow-up time.[8-11] Third, STN-DBS effects on FOG have never 
been compared with continued best medical treatment (BMT) in a controlled design.  
This study aimed to compare the effects of bilateral STN stimulation and continued BMT on 
FOG occurrence in PD patients after 6 and 12 months. Additionally, we compared the effect 
of STN-DBS and continued BMT on FOG severity and disease-related clinical parameters. 
 
PATIENTS AND METHODS 
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Participants. Participants were recruited in the Movement Disorders Clinic of the University 
Hospitals Leuven. All PD patients who were considered eligible for STN stimulation between 
March 1, 2007 and April 1, 2010, were invited to participate. The inclusion criteria were: 1) 
PD diagnosis;[12] 2) disease duration ≥ five years; 3) a combination of disabling motor 
fluctuations and dyskinesias or disabling medication-resistant tremor. The presence of FOG 
was not an inclusion criterion. Both freezers and non-freezers were included in order to 
capture spontaneous or STN-DBS-induced development of FOG.[11]  Patients were excluded 
if they 1) had a mini mental state examination (MMSE) score < 24/30; 2) had severe 
psychiatric problems; 3) were older than 70 years. Informed consent was obtained. 
Participation in the study entailed that the patient could freely choose between undergoing 
DBS and continuing BMT and in both cases agreed to undergo a standardized clinical 
evaluation at baseline and 6 and 12 months later. Continued BMT denoted the use of 
pharmacological compounds, mostly levodopa, aimed at prolonging clinical on periods.[1, 2] 
Both in the DBS and BMT group, adjustments of medication were allowed during the study if 
judged necessary by the treating neurologist (W.V.).  
Standard protocol approvals, registrations, and patient consents. Participants gave 
informed consent consistent with the Declaration of Helsinki. Ethics approval was received 
by the Commissie Medische Ethiek KULeuven.  
Study design and procedures. The design was a prospective, controlled cohort study with a 
consecutive inclusion. Patients were evaluated at baseline (just prior to surgery in the STN-
group) and 6 and 12 months later. At each time point, we evaluated the occurrence and 
severity of FOG by means of the New Freezing of Gait Questionnaire (NFOG-Q),[13] using a 
FOG verification video. The NFOG-Q consists of 3 parts: Part I (item 1) assesses whether 
patients had experienced FOG during the past month during their on and/or off stage; Part II 
(items 2-6) evaluates the frequency and duration of FOG episodes in general as well as during 
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turning and gait initiation separately; 3) Part II (items 7-9) quantifies the impact of FOG on 
patients‟ quality of life. The primary outcome was the occurrence of FOG (0/1 score on item 
1 of the NFOG-Q) at 6 months follow-up, irrespective of whether it occurred on or off 
medication. FOG occurrence after 12 months served as secondary outcome. The tertiary 
outcome was FOG severity in those who reported FOG, assessed by Part II and III of the 
NFOG-Q. Other clinical outcomes were: the Unified Parkinson‟s Disease Rating Scale 
(UPDRS) part III (motor examinations) and part IV (treatment complications), the 
Parkinson‟s Disease Questionnaire-39 (PDQ-39) (quality of life,[14]), the timed get up & go 
test (TUG,[15]) and fall occurrence during the previous three months (score 0= never, 1= 
once, 2= twice or more). Cognitive impairment was measured using the MMSE. Descriptive 
variables included age, gender, disease duration, Levodopa Equivalent Dose (LED) and 
Hoehn and Yahr stage. All evaluations were performed on medication and on stimulation (in 
the intervention group), reflecting the patients‟ status in daily life.  
Operation and DBS parameters. All patients in the STN-group underwent DBS 
implantation by the same neurosurgeon. Patients were off medication for at least 24 hours 
before operation. First the bilateral implantation of a quadripolar electrode (3389, Medtronic 
Inc) in STN was carried out, followed by the implantation of a pulse generator (Kinetra or 
Activa PC, Medtronic Inc.). The stimulator was inserted immediately after electrode 
implantation, or 1 week after stereotactic intervention. Stereotactic localisation of the 
electrodes in the motor part of the STN was determined by MRI, micro-electrode mapping 
and electrical stimulation in the awake patient, using CRW frame (Radionics), Framelink 
(Medtronic Inc.) and microdrive for 5 micro-electrodes (Ben‟s gun). The final electrode 
location was evaluated with postoperative imaging (MRI or CT, fused with preoperative 
MRI). Postoperatively, optimal stimulation parameters were determined considering 
symptoms and side effects. Six months after surgery, most patients were treated with 
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monopolar stimulation (n = 19/24, 79.2%), 60µsec pulse width (n=19/24, 79.2%) and 130 Hz 
stimulation frequency (n=20/24, 83.3%). The mean voltage was 2.5 V, (range 1.1-5.0 V). 
Stimulation settings were largely similar at 12 month follow up.  
Statistical analysis. Data normality was checked using Kolmogorov-Smirnov tests. Baseline 
group differences were studied using Chi-square (X²) statistics, Fisher‟s Exact tests, Wilcoxon 
rank sum tests or unpaired t-tests, as appropriate. Group differences in FOG occurrence and 
severity at six months were examined using Fisher‟s Exact statistics and unpaired t-tests. The 
Cohen effect size, number needed to treat (NNT) and relative risk reduction (RRR) for FOG 
occurrence were determined. Other clinical outcomes with normal distributions were 
compared between groups and time moments using a mixed repeated measures ANOVA 
model. Wilcoxon rank sum between-group comparisons and Friedman within-group analysis 
were applied for not normally distributed clinical variables. 
Generalized Estimating Equations (GEE) models were used to evaluate FOG occurrence over 
time in both groups while controlling for confounders with a post-hoc sequential Bonferroni 
correction for all pairwise comparisons.[16] Main effects of group and time and their 
interaction effect were consecutively entered into the model. The quasi likelihood under 
independence criterion (QIC), an estimate of goodness of fit, proved always better with the 
interaction effect included. We used a Wald X² statistic to investigate the significance of the 
interaction in the GEE model. As the GEE model excludes missing variables, missing data 
points were imputed using the last observation carried forward (LOCF) yielding a worst case 
approach. Intention-to-treat analysis served to investigate whether the results were influenced 
by dropout. GEE statistics with a normal distribution model were used to analyse FOG 
severity. Exploratory analysis were conducted to understand the relation between STN-DBS 
induced conversion from being a freezer to a non-freezer on the one hand and change in 
clinical variables on the other hand using Rank Biserial correlations for binary outcomes 
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(conversion yes/no) in STN-DBS-treated baseline freezers. If appropriate, a multivariate 
analysis was applied next. Statistical analyses were performed using SPSS, version 16. P 
values < 0.05 were considered significant. 
 
RESULTS 
Baseline characteristics. Of the 42 invited patients, one declined to take part in the study. 
Twenty-four patients decided to undergo bilateral STN stimulation and 17 chose to continue 
on BMT. One baseline freezer in the STN-group was lost to follow-up at 6 months, but 
evaluated at 12 months. Five persons in the BMT group, who had FOG at 6 months, were lost 
at 12 months because an STN stimulator (n = 3) or a levodopa/carbidopa enteral infusion 
system (n = 2) was implanted (See Supplement 1 for a flowchart of the study). 
Table 1 shows that STN- and BMT-groups had comparable demographic and clinical profiles 
at baseline, except for LED which was higher in STN- (median = 1113 mg/day) than BMT-
patients (median = 680 mg/day, p=0.0009). There were no group differences in the dose of 
MAO-B inhibitors, amantadine and anticholinergic (N=1) medication (See Supplement 2). 
None of the patients were treated with methylphenidate. There were no baseline group 
differences regarding FOG occurrence (83% in STN-group, 88% in BMT group). All freezers 
had off-FOG and 6 patients in each group also experienced FOG during on. No pure on-FOG 
was observed throughout this study. Baseline characteristics did not differ between patients 
who dropped out of the study and those who completed all three assessments.  
-------------------------------------------------- 
Insert Table 1 about here 
Baseline characteristics 
-------------------------------------------------- 
Freezing of gait occurrence 
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STN-group: Nine out of 20 freezers in the STN-group still had FOG 6 and 12 months after 
surgery, of which 5 cases had FOG during on and off and 4 cases only during off. Eight 
baseline freezers converted to being non-freezers at 6 and 12 months follow-up. Three 
baseline freezers still demonstrated FOG at the 6 months time mark, but had no FOG after 12 
months. Two patients in the STN-group did not have FOG throughout the study period. 
Finally, two baseline non-freezers converted to being freezers, one case with FOG only 
during off and one with FOG during on and off.  
BMT-group: In the BMT-group, all 15 persons who had FOG at baseline continued to have 
FOG during follow-up. Moreover, four of the baseline off-freezers also developed FOG in on 
after 6 and 12 months. Of the 2 baseline non-freezers, one developed FOG during on and off 
at the two follow-up tests resulting in 9 on-and-off-freezers in the BMT-group after 12 
months. One patient showed no freezing at the 3 test moments.  
-------------------------------------------------- 
Insert Figure 1 about here 
FOG occurrence 
-------------------------------------------------- 
Comparison between STN- and BMT-group: First, Fisher Exact Statistics on the primary 
outcome revealed that at six months follow-up, STN-DBS patients were significantly less 
likely to demonstrate FOG than the BMT-group (Table 2). STN surgery was associated with a 
RRR of 0.40 and the number needed to treat was 3 (95% CI, 2 - 10). Similar results were 
obtained at 1-year post-surgery. 
-------------------------------------------------- 
Insert Table 2 about here 
FOG occurrence NNT 
-------------------------------------------------- 
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Second, main and interaction effects of group (STN, BMT) and time (baseline, 6 months, 12 
months) on FOG occurrence were investigated via the GEE model. A significant interaction 
effect was found on the dataset with imputed cases (dropout at 6 months: N=1, at 12 months: 
N=5) in favour of the STN-group (Wald X²= 7.86; p = 0.02). Post-hoc comparisons showed 
that patients in the STN-group were less likely to freeze at 6 month follow-up (mean 
difference = -2.03; 95% CI (-3.99 – -0.07); p = 0.04) compared with the BMT-group (Figure 
1). After adjustment for baseline differences in LED scores, the interaction effect of 
group*time was no longer significant (Wald X² = 1.12; p = 0.57).  
The difference in FOG occurrence between groups was more pronounced at 12 months 
follow-up (mean difference = -2.53; 95% CI (-4.54 – -0.53); p = 0.01). We found a significant 
within-group reduction in FOG occurrence in the STN- but not in the BMT-group (Wald X² = 
7.65; p = 0.02). In the STN-group, improvement in FOG occurrence was borderline 
significant at 6 month follow-up (mean difference = -1.27; 95% CI (-2.57 – 0.02); p = 0.05), 
and significant at 12 months follow-up (mean difference = -1.78; 95% CI (-3.14 – -0.41); p = 
0.01) compared to baseline (Figure 1). 
Freezing of gait severity. FOG severity, analysed in freezers only, was significantly different 
between groups 6 months postoperatively (t = 2.89, p = 0.008), and borderline significant at 
12 months (t = 2.06, p = 0.05). Similar to FOG occurrence, the GEE model produced a 
significant interaction effect of group*time based after imputation of missing data (Wald X² = 
6.51; p = 0.04). Figure 2 shows the post-hoc comparisons of the GEE model. At six months 
follow-up, the STN-group reported significantly less FOG severity (34.2% of the baseline 
score) than the BMT-group (mean difference = -5.89 points on NFOGQ; 95% CI (-9.70 – -
2.09); p = 0.03). These differences were maintained at 12 months follow-up (mean difference 
= -7.05; 95% CI (-11.38 – -2.71); p = 0.02). The interaction effect of group*time was no 
longer significant when accounted for baseline LED (Wald X² = 1.68; p = 0.43). 
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No within group changes were observed in BMT-group, while the STN-group obtained better 
NFOGQ total scores at 12 months follow-up (mean difference = -5.70; 95% CI (-9.35 – -
2.04); p = 0.03) compared to baseline. There was a trend towards improvement (mean 
difference = -4.79; 95% CI (-8.30 – -1.28); p = 0.06) in the STN-group from baseline to 6 
month follow-up.  
-------------------------------------------------- 
Insert Figure 2 about here 
FOG severity 
-------------------------------------------------- 
Clinical evaluation 
 Several clinical measures improved at follow-up in the STN- but not in the BMT-group 
(Table 1). As expected, LED doses were reduced in the STN-group 6 and 12 months post-
surgery compared to baseline (63.1 and 61.3% reduction respectively, p<0.01) and BMT 
(p<0.01). The distribution of other medication doses remained similar between groups except 
for amantadine which was more frequently administered in the BMT compared to the STN-
group (p=0.04) at 12 months (See Supplement 2). Additionally, UPDRS motor scores, on/off 
fluctuations (UPDRS IVb) and PDQ-39 scores showed significant improvements at 6 and 12 
month follow-up compared to baseline (p<0.01 for all comparisons), resulting in lower 
(better) scores than the BMT-group. In the BMT-group, MMSE scores had worsened at 12 
months compared to 6 months and baseline assessment (p=0.02). No effects on timed gait 
tests or falls were shown. 
 
Association between improvement in FOG and clinical outcomes following STN-DBS. 
We examined which clinical factors predicted the conversion from freezer to non-freezer 
Freezer-to-non-freezer conversion at 6 months was marginally correlated with baseline LED 
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(R=0.45, p=0.05), meaning that freezers with a higher baseline LED had a higher likelihood 
of converting to being a non-freezer after STN-DBS. There were no significant correlations 
with the change in other clinical variables, including LED change and other UPDRS IVb. 
Freezer-to-non-freezer conversion at 12 months was significantly correlated with the relative 
reduction in LED (expressed as percentage of baseline LED, R=0.46, p=0.04) and with the 
reduction in on/off fluctuations (UPDRS IVb scores, R=0.47, p=0.03), meaning that freezers 
with a more pronounced reduction in LED and on/off fluctuations at 12 months follow-up 
have a higher likelihood to have become a non-freezer at this time point. Other correlations 
were not significant. To further examine the relative independence of LED-reduction and 
UPDRS IVb-reduction in explaining the freezer-to-non-freezer conversion, we applied a 
multivariate logistic regression model including these two factors. In this full model 
regression analysis, the change in UPDRS IVb scores entered the model first and explained 
21% of the variance between „converters‟ and „non-converters‟ (R²=0.21, p=0.037). Next, the 
LED reduction entered the model and proved a secondary, independent factor explaining an 
additional 20% of variance (R²=0.20, p=0.026). Jointly, the two factors explained 41% of the 
variance between „converters‟ (N=11) and „non-converters‟ (N=9).  
 
DISCUSSION 
This is the first prospective, controlled study into the effect of bilateral STN stimulation on 
self-reported freezing of gait (FOG) as experienced in daily life. The results were in favour of 
STN-DBS. Following surgical treatment, freezers were more likely to 1) convert to being 
non-freezers (RRR=0.4) and 2) experience a reduction in FOG severity. These effects were 
mediated by a reduction in patients‟ LED and motor fluctuations. Patients who continued 
BMT showed worsening of FOG symptoms (more on/off FOG). In agreement with previous 
jnnp-2013-306336-R1    Vercruysse 12 
 
  
literature,[6, 7] we found that STN-DBS also led to improved motor symptom severity and 
quality of life.  
As quality of life improvement is a well-established finding,[7] the current study examined 
the effects of STN-DBS on FOG in a non-randomized way for ethical reasons. This induced a 
small difference in subject number between groups at baseline. Patients who chose to undergo 
STN-DBS were comparable to BMT-treated patients at baseline on all clinical parameters, 
except for their higher LED score. It is noteworthy that this suggests a slightly more severe 
disease profile in the STN-DBS group, adding strength to the positive treatment outcomes 
found in this group. We did not assess FOG in a blinded way which is a limitation of the 
current study.[1] However, the NFOGQ is a validated tool to evaluate FOG occurrence and 
severity over a period of 1 month rather than in a single test session, which adds to the 
ecological validity of the findings.[13]  
The present study suffered from dropout (N=5) in the control arm due to the natural 
progression of the disease. We performed a thorough and conservative statistical control for 
this drawback, through imputation and GEE-modeling. Therefore, it is unlikely that dropout 
influenced the interpretation of the results. 
The mainstay of therapy for FOG is to prolong clinical „on‟ periods.[1] Stimulating the STN 
does not directly produce striatal dopamine release but may boost the dopamine motor system 
by inhibiting overexcited STN neurons,[5, 17] reducing the neuronal synchronization in the 
vicinity of STN, [18] and altering connectivity of thalamocortical pathways.[19] Similarly, 
methylphenidate, which enhances synaptic dopamine, was recently suggested to improve 
FOG in combination with levodopa and STN-DBS.[20]. Still, response to STN-DBS in 
relation to FOG is heterogeneous with pre-surgical levodopa-responsiveness, disease duration 
and age as best predictors of outcome.[11, 21] An important finding of the present study was 
that the reduced levodopa dose equivalent and improved motor fluctuations discriminated 
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between baseline freezers who no longer experienced FOG 12 months after surgery (55%) 
and those who did (45%). This is in line with a recent multivariate model in which increased 
LED, over and above its reflection of disease severity, was a significant predictor of 
FOG.[22] On the other hand, a meta-analysis of long-term effects of DBS of STN and 
GPi,[23] suggested that the reduced levodopa dosages, enabled by STN-DBS, may be 
responsible for a quicker reappearance of postural and gait disturbances as compared to GPi-
stimulated subjects after 2 years. These findings support the complex relationship between 
FOG and levodopa, suggesting that FOG is partially levodopa-responsive and partially 
dependent on other neurotransmitter systems with extremes at both ends of the spectrum.[1, 
2] 
Our results of post-surgical improvement of FOG severity substantiate recent findings of Niu 
et al.,[24] who examined a similar follow-up period, but no control group and no freezer to 
non-freezer conversion. FOG can also emerge after STN stimulation.[11, 25] In our STN-
DBS-group 2 of the 4 non-freezers at baseline developed FOG after surgery. Similarly, one of 
the 2 baseline non-freezers in the BMT group demonstrated FOG at 6 and 12 months follow-
up. Emergence of FOG in some patients after STN stimulation may reflect disease 
progression rather than a side effect of stimulation, although our sample of non-freezers was 
too small to make firm conclusions. In the BMT-group, disease progression was reflected by 
the increase from 2 to 6 patients experiencing FOG in both on and off.  
Freezers treated with STN-DBS who had converted to being non-freezers at 12 months 
follow-up all had stimulation frequencies of 130 Hz (n=11) or more (n=2). This result is 
interesting in the light of recent studies that suggest controversial results on lowering the 
stimulation frequency to specifically target axial symptoms and FOG in the short and/or long 
term.[8, 9, 10, 26, 27]   
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Clinically, FOG is influenced by a range of motor and non-motor problems which may 
respond differently to STN-DBS.[1, 22] The central motor component of FOG relates to poor 
control of timing and scaling of movement which predisposes freezers‟ locomotor pattern and 
other repetitive movements to a critical breakdown.[1, 28-30] In the context of freezing 
during upper limb motion, we recently showed that patients with FOG overactivated the STN, 
pallidum and putamen while prefrontal motor regions were underactivated compared to non-
freezers and controls.[31] As such, freezing-related alterations of brain activity were located 
within the striatofrontal circuitry which is likely to be influenced by STN-DBS. Positive 
effects of STN-DBS on stride length,[32] bilateral coordination,[33] symmetry,[32] and 
turning [34] have been reported and could thus diminish FOG after STN-DBS. However, 
improvements of timed gait in the STN-group in this study did not reach significance, 
suggesting a FOG-specific effect of STN-DBS as an alternative explanation. In line with 
recent neuroimaging studies suggesting a supplementary role of nondopaminergic locomotor 
circuitries,[35-37] low frequency stimulation of the PPN, may alleviate FOG without 
necessarily recovering background spatiotemporal gait abnormalities.[38] Moreover, novel 
DBS approaches that simultaneously modulate gait control networks through STN, SNr and 
PPN [39, 40] may produce a synergistic effect on FOG.    
 
CONCLUSION 
In this prospectively controlled study, STN-DBS alleviated FOG in 55 % of freezers at 6 and 
12 months after surgery compared to worsening of FOG when treated with BMT. Freezers 
treated with STN-DBS were also more likely to experience reduced FOG severity during 
follow-up compared to patients who stayed on BMT. The improvement of FOG after STN-
DBS may be partially driven by the dopamine-reducing effects and reduced on/off 
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fluctuations. Future follow-up trials are warranted to evaluate if therapeutic benefits persist 
with disease progression. 
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Tables  
Table 1 Clinical characteristics of the STN- and BMT-groups at baseline, 6 and 12 months 
follow-up.  
aRepeated measures ANOVA tests with Time (T0, T1, T2) as within-subject and Group (STN, BMT) 
as between-subject factors were used. Reported p-values are based on Tukey HSD post-hoc 
comparisons. bChi-square test was used for between-group comparison. cGEE model was used (see 
text). dNon-parametric tests were used for between-group comparisons (Wilcoxon rank sum test) and 
within-group analysis (Friedman test with Wilcoxon paired t-test for post-hoc comparisons) over T0, 
T1 and T2.   
   STN-group 
(n = 24) 
 BMT-group 
(n = 17) 
Group comparison 
 T0 
Baseline 
T1 
6 months 
T2 
12 months 
T0 
Baseline 
T1 
6 months 
T2 
12 months 
T0 T1 T2 
Age 
(years) 
Meana 
(Stdev) 
58.33 
(+/-9.56) 
- - 58.12 
(+/-6.57) 
- - 0.94   
Gender 
(m/f) 
Freq.b 14/10 - - 8/9 - - 0.48   
DD 
(years) 
Meana 
(Stdev) 
11.88 
(+/- 5.10) 
- - 12.47 
(+/-4.10) 
- - 0.40   
Freezing 
(yes/no) 
Freq.c 20/4 14/101 11/131 15/2 16/1 16/1 1.0 0.01 0.01 
H & Y on 
(range, 0 – 5) 
Mediand 
(IQR) 
2.75 
(2.00-3.00) 
2.5 
(2.00-3.00) 
2.5 
(2.0-3.0) 
2.5 
(2.0-3.0) 
2.5 
(2.0-3.0) 
2.5 
(2.5-3.0) 
0.82 0.74 0.56 
UPDRS III 
(range, 0 – 108) 
Meana 
(Stdev) 
31.13 
(+/-15.23) 
22.921 
(+/-8.42) 
21.381 
(+/-8.93) 
26.47 
(+/- 14.72) 
30.41 
(+/-11.71) 
31.29 
(+/-10.38) 
0.81 0.35 1.0 
UPDRS IV 
(range, 0 – 23) 
Meana 
(Stdev) 
9.29 
(+/-2.94) 
4.081 
(+/-3.56) 
3.381 
(+/-2.32) 
9.24 
(+/-1.78) 
9.47 
(+/-2.72) 
9.71 
(+/-1.96) 
1.0 <0.01 <.0.01 
LED*1 
(mg/day) 
Mediand 
(IQR) 
1112.5 
(780-1369.2) 
410.01 
(208.5-458.3) 
430.01 
(208.5-557.5) 
680.0 
(515-780) 
606.6 
(515-866.7) 
615.0 
(515-915) 
<0.01 <0.01 <0.01 
Falls 
(range 0 – 2) 
Mediand 
(IQR) 
0 
(0-1) 
0 
(0-2) 
0 
(0.00-1.25) 
1 
(0-2) 
0 
(0-1) 
1 
(0-2) 
0.12 0.80 0.55 
TUG*2 
(seconds) 
Meana 
(Stdev) 
13.09 
(+/-9.93) 
10.90 
(+/-2.84) 
10.81 
(+/-4.31) 
11.53 
(+/-3.55) 
11.79 
(+/-3.31) 
11.49 
(2.96) 
0.94 1.0 1.0 
MMSE 
(range, 0 – 30) 
Mediand 
(IQR) 
29 
(28.75-30) 
29.50 
(28.75-30.00) 
29 
(28-30) 
30 
(29-30) 
30 
(29-30) 
291,2 
(28-29) 
0.12 0.60 0.31 
PDQ-39*3 
(range, 0 – 800) 
Meana 
(Stdev) 
280.69 
(+/-116.39) 
189.941 
(+/-8.63) 
185.331 
(+/-111.00) 
341.86 
(+/-105.86) 
332.92 
(+/-123.29) 
315.88 
(+/-112.74) 
0.58 <0.01 0.01 
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Abbreviations: BMT = best medical treatment; freq.= frequencies; DD= disease duration; H&Y: 
Hoehn and Yahr; LED = Levodopa Equivalent Dose; TUG= Timed up and go; MMSE = Mini Mental  
State Examination; PDQ-39 = Parkinson‟s Disease Quality of Life Questionnaire; STN = subthalamic 
nucleus; UPDRS = Unified Parkinson‟s Disease Rating Scale. 
1P-value < 0.05 compared to T0. 2P-value < 0.05 compared to T1. 
*1: 5 missing LED values in the BMT-group were imputed using LOCF method. Results were similar 
without imputation. *2: 1 missing TUG score in the BMT-group was imputed using LOCF method. 
Results were similar without imputation. *3: 1 missing PDQ-39 score in the STN-group was imputed 
using LOCF method. Results were similar without imputation. 
 
Table 2. Freezing of Gait occurrence at 6 and 12 months follow-up in the STN- and BMT-
group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  6 months follow-up         12 months follow-up 
Freezing of Gait  STN-group 
N = 23 
BMT-group 
N = 17 
 STN-group 
N = 24 
BMT-group 
N = 12 
Freezing, n (%)  13 (57%) 16 (94%)  11 (46%) 11 (92%) 
No freezing, n (%)  10 (43%) 1 (6%)  13 (54%) 1 (8%) 
Test statistic, p value  Fisher‟s Exact, p = 0.01  Fisher‟s Exact, p = 0.01 
Effect size  1.38  1.41 
Number Needed to Treat  3 (2 – 10)  2 (2 – 8) 
Relative Risk Reduction  0.40 (0.12 – 059)  0.50 (0.20 – 0.69) 
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Figure legends 
 
 
Figure 1. Occurrence of freezing of gait in the STN-group (n = 24) and BMT-group (n = 17) 
at baseline, 6 and 12 months follow-up.  
 
 
* FOG occurrence of 1 freezer in the STN-group was imputed at 6 month follow-up. 
† FOG occurrence of 5 freezers in the BMT-group was imputed at 12 month follow-up. 
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Figure 2. Freezing of gait severity in the STN- (n = 11) and BMT-group (n = 15) at baseline, 
6 and 12 month follow-up. 
 
 
